Assembly Biosciences Acquisition | Healthcare Deal in CA

Assembly Biosciences has completed the acquisition of Assembly Biosciences, a healthcare services other business in California, for $115.0 million. Assembly Biosciences is a biotechnology company developing therapeutics for serious viral and liver diseases, supporting clinical development of pipeline candidates. The company’s healthcare services other focus in South San Francisco, CA aligns with broader healthcare M&A and other acquisition activity tied to advancing medical programs. The closed underwritten registered offering included 3,924,624 shares of common stock priced at $26.50 and pre-funded warrants for up to 415,000 shares, with full exercise of the underwriters’ option to purchase 566,040 additional shares. Net proceeds are intended for clinical development and general corporate purposes, with joint book-running managers including Guggenheim Securities and UBS Investment Bank and additional management by Mizuho and H.C. Wainwright & Co.